Background Hyperhomocysteinaemia may constitute an independent risk factor for cardiovascular disease, but it is still unclear by which pathophysiological mechanisms homocysteine (tHcy) may promote atherothrombosis. The aim of this study was ®rstly to examine whether tHcy is associated with endothelial dysfunction, increased adherence of leukocytes, and/or chronic low-grade in¯ammation, as estimated from plasma levels of von Willebrand factor (vWf), soluble vascular cell adhesion molecule 1 (sVCAM-1) and C-reactive protein (CRP), respectively. Secondly we investigated whether the presence of type 2 diabetes modi®es these associations.
Introduction
Many studies provide evidence for an independent association between hyperhomocysteinaemia and atherothrombotic disease, as recently reviewed [1] . However, the strength of the association between an elevated total homocysteine (tHcy) concentration and cardiovascular disease seems to vary among populations [2] . Four recent studies in populations with diabetic subjects demonstrated that hyperhomocysteinaemia is a strong risk factor for cardiovascular disease in subjects with type 2 diabetes [3±6]. For diabetic subjects, tHcy appeared to be a 1´6-fold stronger risk factor for cardiovascular disease than for non-diabetics [3] .
tHcy is derived metabolically from the essential amino acid methionine. Homeostasis of methionine-homocysteine metabolism is complex and is in¯uenced by demographic, genetic, and acquired factors. It is not fully understood by which pathophysiological mechanisms tHcy promotes atherothrombosis in humans. Recent studies suggest that tHcy is a vasculotoxic molecule that mediates its adverse vascular effects by causing endothelial damage [7±13] . Impairment of regulatory functions of the endothelium is a key event in current models of atherothrombosis [13] . In addition, tHcy may cause an increased adherence of leukocytes to the endothelium, mediated by an increased expression of adhesion molecules, as observed in early atherosclerosis [13±15] . An alternative hypothesis is that tHcy induces a chronic low-grade in¯ammation, thus promoting the atherogenetic process [13] .
Previous studies concerning the pathophysiological mechanisms by which tHcy may promote atherothrombosis have either examined a study group that was not population-based or did not assess the strength of the association separately for type 2 diabetes and non-diabetics [7±12] . The latter is important because diabetes and tHcy seem to interact [3] . Therefore, we assessed, in a population-based study that was strati®ed for glucose tolerance [16] , the association between tHcy level and endothelial dysfunction by measuring plasma levels of the endothelium-derived regulatory protein, von Willebrand factor (vWf). We also assessed the association between tHcy and the soluble form of vascular cell adhesion molecule 1 (sVCAM-1) as an estimate of the adherence and transendothelial migration of leukocytes; and ®nally, between tHcy and C-reactive protein, a marker of chronic low-grade in¯ammation. The use of these protein markers is supported by studies showing an association between high plasma or serum levels of these proteins and an increased risk of cardiovascular disease [17±26].
Methods

Subjects
The study population consisted of an age-, sex-, and glucose-tolerance-strati®ed sample of the Hoorn Study, a population-based study of glucose tolerance and other cardiovascular risk factors in a 50-to 75-year-old general Caucasian population conducted from 1989±1992, as described previously [16] .
Brie¯y, 2484 subjects (71% of those invited) participated. All subjects, except previously diagnosed diabetic subjects treated with oral glucose-lowering agents or insulin, underwent an oral glucose tolerance test (OGTT) according to the WHO guidelines [27] . For reasons of ef®ciency, subjects with a 2-h postload glucose $ 7´5 mmol L
À1
, all subjects with type 2 diabetes and a random sample of subjects with a 2-h postload glucose < 7´5 mmol L À1 strati®ed by age and sex were invited within 4 weeks for a second visit to investigate glucose-intolerance-related complications (709 invited, of whom 631 À 89% À participated). These subjects underwent a second OGTT (except those who already used blood glucose lowering agents; n 67). On the basis of the mean of the two OGTTs, glucose tolerance was divided into three categories [16] : normal glucose tolerance (n 288), impaired glucose tolerance (n 170) and type 2 diabetes (n 173). Subjects with normal or impaired glucose tolerance or type 2 diabetes in the present study population thus represented a strati®ed random sample of all subjects with normal or impaired glucose tolerance or type 2 diabetes in the initial cohort.
The Hoorn Study was approved by the Ethical Review Committee of the University Hospital Vrije Universiteit. Informed consent was obtained from all participants.
Laboratory and clinical assessments
After an overnight fast, blood was drawn from an antecubital vein. We measured tHcy, vWf, VCAM-1, CRP, glucose, creatinine, albumin, urea nitrogen and lipids. No plasma was available for 21 subjects for the measurement of vWf, sVCAM-1 and CRP. Concentrations of serum total (free plus protein bound) tHcy were assessed in frozen (À 20 8C) EDTA serum by using high-performance liquid chromatography with¯uorescence detection [28] . The intra-and interassay coef®cients were 2´1% and 5´1%, respectively. Plasma concentrations of von Willebrand factor (vWf) and C-reactive protein (CRP) were assessed as previously described [26] . VWf is expressed in IU mL À1 of vWf antigen by comparison to the 4th International Standard for vWf in plasma [26] . The intra-and interassay coef®cients of variation of CRP were 3´8% and 4´7%, respectively. Concentrations of sVCAM-1 were assessed in deep frozen (À 70 8C) heparin plasma samples. Concentrations of sVCAM-1 were measured, in duplicate, by ELISA kits (Bender MedSystems, Wenen, Austria; reference plasma values in 111 healthy subjects, as provided by the manufacturer, 1090 6 237 ng mL À1 ; range 675±1693). We measured sVCAM-1 levels in 27 healthy volunteers and found a mean level of 966 ng mL À1 with an intra-and interassay coef®cient of variation of 3´4% and 14%, respectively [23] . Serum total cholesterol, HDL cholesterol, and triglycerides levels were all measured as described elsewhere [3] . We estimated the glomerular ®ltration rate by the method of Levey et al. which is thought to be more accurate than the Cockcroft±Gault formula [29] . Blood pressure was measured as the mean of four measurements performed on two different occasions, using a random-zero sphygmomanometer under standardized conditions. Hypertension was de®ned as a blood pressure $ 160 mmHg systolic and/or $ 95 mmHg diastolic and/or the current use of antihypertensive medication. Subjects were classi®ed as current cigarette smokers or nonsmokers. Body mass index (BMI) and waist-to-hip ratio (WHR) were calculated as described elsewhere [16] . ABO blood groups were determined by standard agglutination techniques using commercial test erythrocytes.
Statistical analysis
Variables are presented as mean 6 standard deviation (SD), number (percentage of the total), or, in case of a skewed distribution, the median and the interquartile range (IQR). To study whether tHcy is independently related to vWf, VCAM-1 and CRP, and whether this differs between subjects with type 2 diabetes and those with impaired or normal glucose tolerance, we constructed crude and adjusted regression models. Analyses adjusted only for the strati®cation variables age, sex and glucose tolerance (i.e. normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes) were used to study the relation between the outcome variables (vWf, VCAM-1, CRP) and possible determinants thereof: tHcy, glomerular ®ltra-tion rate (GFR), smoking, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, systolic and diastolic blood pressure, hypertension, BMI and the WHR. For variables that did not have a normal distribution of the residuals, the logarithmically transformed data were used for a better ®t of the data. Possible determinants measured on a continuous scale were used as such in the regression models. For each dependent variable three regression models were made. The regression analyses were primarily adjusted for the strati®cation variables, secondarily for all determinants with a P-value < 0´15 in the crude analysis and current smoking, and thirdly for other variables of pathophysiological interest [30] . The residuals were checked for a normal distribution and a constant variance. In addition, to check whether there was a threshold in the relation between tHcy and the dependent variables, we performed analyses in which we divided tHcy into four
, respectively). To ascertain whether the presence of cardiovascular disease at enrolment disturbed the results, we performed the same analysis as described above for the subjects with and without a history of cardiovascular disease. Cardiovascular disease was de®ned as coronary artery disease, cerebrovascular disease and or peripheral arterial disease as described before [3] . vWf depends on blood group, and therefore we 
Data are presented as mean (SD), percentage of the total or median (interquartile range). *Estimated by the method of Levey et al. [29] , ²median (interquartile range). BMI, body mass index; WHR, waist-to-hip ratio; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipoprotein cholesterol. performed strati®ed analyses for the different blood groups to investigate if blood group modi®ed the association between tHcy and vWf. Finally we investigated whether glucose tolerance was an effect modi®er of the tHcy-outcome relationships by adding product terms to the analysis (i.e. product terms of tHcy with impaired glucose tolerance and tHcy with type 2 diabetes). With an F-test we checked whether these product terms signi®cantly improved the model. All analyses were performed with the SPSS. Twosided P-values less than 0´05 were considered to be statistically signi®cant.
Results Table 1 shows the characteristics of the participants. Twenty-one subjects had missing blood samples, so we obtained complete data in 610 participants, 170 (28%) of whom had type 2 diabetes. The median tHcy serum level was 11´4 (IQR: 9´3±14´1) mmol L À1 . One hundred 25 (21%) subjects had a tHcy level $ 15 mmol L À1 , the cutoff value frequently used to de®ne a high tHcy level [1±31].
tHcy was signi®cantly but weakly associated with vWf (b 0´198; P 0´004; Fig. 1a ; Table 2a ) after adjustment for the strati®cation variables. Adjustment for other possible confounders, especially GFR, weakened this association (b 0´150; P 0´046), but it remained signi®cant. A 50% increase in the concentration of tHcy was associated with an increase in the concentration of vWf with 0´08 IU mL À1 . Thus, for example, when the concentration of tHcy increased from 10 to 15 mmol L
À1
, the level of vWf increased with 0´08 IU mL À1 (95% con®dence interval (C.I.), 0´01±0´22 IU mL
). In comparison, type 2 diabetes, as compared to normal glucose tolerance, was associated with a 0´39 IU mL À1 (95% C.I., 0´23±0´56 IU mL À1 ) higher vWf level, after adjustment for age, sex, current smoking, LDL cholesterol and GFR, but the presence of diabetes did not modify the association between tHcy and vWf (P-interaction 0´34 after exclusion of one diabetic subject with an extremely high tHcy level).
After adjustment for the strati®cation variables there was a signi®cant but weak association between tHcy and sVCAM-1 (b 0´130; P 0´001). Adjustment for other possible confounders, especially GFR, weakened this association (b 0´082; P 0´041; Fig. 1b; Table 2b ), but it remained signi®cant. For example, when the concentration of tHcy increased from 10 to 15 mmol L À1 , the concentration of sVCAM-1 increased with 60´9 mg L À1 (95% C.I., 19´6±144´6 mg L
). In comparison, type 2 diabetes, as compared to normal glucose tolerance, was associated with a 146´2-mg L À1 (95% C.I. 30´9±270´8 mg L À2 ) higher sVCAM-1 level, after adjustment for age, sex, current smoking, LDL cholesterol, HDL cholesterol, GFR, BMI and hypertension, but the presence of diabetes did not modify the association between tHcy and sVCAM-1 (Pinteraction 0´79).
There was no signi®cant association of tHcy with CRP in any model ( Fig. 1c; Table 2c ). When the concentration of tHcy increased from 10 to 15 mmol L À1 , the concentration of CRP increased with 0´01 mg L À1 (95% C.I., À 0´01± 0´01 mg L
). In addition, the presence of diabetes did not modify the association between tHcy and CRP (P-interaction 0´17).
The results did not differ signi®cantly between the subjects with and without cardiovascular disease at enrolment (data not shown). In addition, the relation between vWf and tHcy was not modi®ed by blood group (data not shown).
Our analysis did not suggest any threshold in the relation between tHcy and the dependent variables (data not shown). 
Discussion
This is the ®rst study that evaluates the association between tHcy and markers of endothelial function, leukocyte adhesion and low-grade in¯ammation in a population-based study with a focus on diabetes.
Hyperhomocysteinaemia may predispose to atherothrombosis by injuring the vascular endothelium. We assessed endothelial function by measuring vWf, an endothelial protein, increased levels of which are associated with an adverse cardiovascular outcome [17±19, 26,32± 35] . We found that tHcy was associated with a signi®cant, but small change in the vWf concentration. If we assume that this association is causal, a relatively large increase in tHcy (which is clearly associated with increased mortality in this population [36] ) induces a relatively minor increase in vWf. Such minor increases in vWf were not strongly associated with increased mortality in the present population, because the association between vWf and mortality was non-linear and restricted to subjects with vWf > 1´56 IU/mL [26] . Accordingly, our results suggest that if tHcy does in fact induce endothelial dysfunction, this is not re¯ected by an increased level of vWf. Three previous studies concerning vWf and tHcy showed a positive correlation in subjects with peripheral arterial occlusive disease [7±9] . In contrast, a study in hyperlipidaemic male smokers showed a signi®cant negative correlation between tHcy and vWf [37] . A recent study performed by de Roo et al. demonstrated a weak positive relation between tHcy and the endothelial proteins vWf and endothelin in healthy ) associated with a Model b ln tHcy (95% C.I.) P-value 50% increase in tHcy
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance, age and sex. Model 2: as model 1 plus the variables with a P-value < 0´15 in the crude analysis (LDL cholesterol, glomerular ®ltration rate) and current smoking. Model 3: as model 2 plus other variables of interest (body mass index, waist-to-hip ratio, hypertension, HDL cholesterol). Table 2b Multiple linear regression analysis with ln soluble vascular cell adhesion molecule 1 (sVCAM-1 in mg/L) as the outcome variable and tHcy as the independent variable of interest
) associated with Model b ln tHcy (95% C.I.) P-value a 50% increase in tHcy
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance, age and sex. Model 2: as model 1 plus the variables with a P-value < 0´15 in the crude analysis (current smoking, LDL cholesterol, HDL cholesterol, glomerular ®ltration rate, body mass index, hypertension). Model 3: as model 2 plus other variables of interest (waist-to-hip ratio). ) associated with a Model b ln tHcy (95% C.I.) P-value 50% increase in tHcy
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance, age and sex. Model 2: as model 1 plus the variables with a P-value < 0´15 in the crude analysis (current smoking, body mass index, waist-to-hip ratio, HDL cholesterol, hypertension). Model 3: as model 2 plus other variables of interest (glomerular ®ltration rate, LDL cholesterol).
postmenopausal women [38] . Taken together, these studies and the current data suggest that there is a weak association between tHcy and vWf in the general (mostly healthy) population, and that this association may be magni®ed in the presence of other factors, such as peripheral arterial occlusive disease. This would be consistent with studies suggesting that mild hyperhomocysteinaemia, at least in some populations, appears more strongly associated with the progression of atherothrombotic disease than with its initiation [39±41] . As the prevalence of cardiovascular disease was 10´6% [3] , our study lacked power to investigate this issue, but this hypothesis clearly requires further study.
We examined whether hyperhomocysteinaemia was associated with an increased recruitment of leukocytes as re¯ected by plasma levels of sVCAM-1, a member of the immunoglobin superfamily that plays an important role in the recruitment of mononuclear leukocytes to the endothelium [14, 15] . A 50% increase in tHcy was associated with a 60´9 mg L À1 increase in sVCAM-1 levels, which corresponds with a 6% increase in 7-year mortality risk [23] . This weak association between tHcy and sVCAM-1 does not provide strong evidence in favour of the hypothesis that tHcy is associated with an increased adherence of leukocytes to the endothelium, a hypothesis recently proposed by Dudman [42] . Our ®nding is in line with a recent study that demonstrated a signi®cant association between sVCAM-1 and carotid intimal medial thickness, a surrogate measurement of early atherosclerosis, but not between sVCAM-1 and tHcy [21] .
We further investigated whether tHcy was related to CRP. CRP is an acute phase reactant and increased levels may re¯ect a chronic low-grade in¯ammatory state. Increased CRP levels have been shown to be an independent predictor of atherothrombotic events [19,24±26,43±46] . In the population investigated, tHcy was not associated with CRP. This may imply that hyperhomocysteinaemia does not promote atherothrombosis by contributing to lowgrade in¯ammation.
Kuller et al. have argued that the relation between tHcy and atherogenesis may not be causal, but, that conversely, vascular disease may induce an increase in the concentration of tHcy [47] . They suggest that the in¯ammation in atherosclerosis is associated with an increased mitotic activity and results in a shortage of folic acid, which is used in DNA synthesis. Folic acid is also essential in the metabolism of tHcy and the increased demand on folic acid would lead to a secondary elevation of tHcy levels. To test this theory we performed a multiple regression analysis with CRP as the independent and tHcy as the dependent variable. However, this analysis also did not suggest a relation between tHcy and CRP (data not shown).
A shortcoming of this study might be that folate, vitamin B6 and B12 status were not measured. Although there is no evidence that inadequate B-vitamin status can directly cause a raise in plasma vWf, sVCAM-1 or CRP, we cannot fully exclude this.
In conclusion, this study provides evidence that, in a general population of middle-aged and elderly subjects with and without type 2 diabetes, tHcy is, at most, weakly associated with endothelial dysfunction as estimated from plasma vWf, and with leukocyte adhesion as estimated from plasma sVCAM-1. tHcy was not associated with chronic low-grade in¯ammation as estimated from plasma CRP. Our data thus suggest that the link between tHcy and atherothrombosis cannot be explained by associations of tHcy with vWf, sVCAM-1 or CRP. We cannot exclude that these associations may be stronger in speci®c patient groups. The present data do provide evidence against the hypothesis that the chronic low-grade in¯am-mation that is part of the atherosclerotic process is itself a determinant of tHcy levels.
